MA50159A - Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps - Google Patents
Nouvelles combinaisons stables de charpentes de domaines variables d'anticorpsInfo
- Publication number
- MA50159A MA50159A MA050159A MA50159A MA50159A MA 50159 A MA50159 A MA 50159A MA 050159 A MA050159 A MA 050159A MA 50159 A MA50159 A MA 50159A MA 50159 A MA50159 A MA 50159A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- frames
- new stable
- variable areas
- stable combinations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17192206.5A EP3459968A1 (fr) | 2017-09-20 | 2017-09-20 | Nouvelles combinaisons de structure de domaines variables d'anticorps stables |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50159A true MA50159A (fr) | 2020-07-29 |
Family
ID=59982265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050159A MA50159A (fr) | 2017-09-20 | 2018-09-19 | Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps |
Country Status (8)
Country | Link |
---|---|
US (2) | US11421035B2 (fr) |
EP (2) | EP3459968A1 (fr) |
JP (2) | JP2020535799A (fr) |
CN (1) | CN111133000A (fr) |
AU (1) | AU2018335823A1 (fr) |
CA (1) | CA3073882A1 (fr) |
MA (1) | MA50159A (fr) |
WO (1) | WO2019057787A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL243311B (en) * | 2013-06-26 | 2022-07-01 | Numab Therapeutics AG | New frameworks for antibodies |
EP3816185A1 (fr) | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur |
EP3915580A1 (fr) | 2020-05-29 | 2021-12-01 | Numab Therapeutics AG | Anticorps multi-spécifique |
EP3988568A1 (fr) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Traitement combiné |
EP4019090A1 (fr) | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Domaines variables d'anticorps liant il-4r |
EP4019546A1 (fr) | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Domaines variables d'anticorps qui se lient à il-31 |
WO2022136693A1 (fr) | 2020-12-23 | 2022-06-30 | Numab Therapeutics AG | Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite |
EP4019547A1 (fr) | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Anticorps multispécifiques ayant une spécificité pour il-4r et il-31 |
JP2024501656A (ja) | 2020-12-23 | 2024-01-15 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | Il-4rに結合する抗体可変ドメイン |
EP4288451A1 (fr) | 2021-02-02 | 2023-12-13 | Numab Therapeutics AG | Anticorps multispécifiques ayant une spécificité pour ror1 et cd3 |
MX2023009484A (es) | 2021-02-12 | 2023-11-09 | Boehringer Ingelheim Int | Proteinas de union al antigeno complemento c3. |
EP4183800A1 (fr) | 2021-11-19 | 2023-05-24 | Medizinische Hochschule Hannover | Nouveaux anticorps neutralisants du sars-cov-2 |
EP4273162A1 (fr) | 2022-05-06 | 2023-11-08 | Numab Therapeutics AG | Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite |
WO2023214047A1 (fr) | 2022-05-06 | 2023-11-09 | Numab Therapeutics AG | Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite |
WO2024038095A1 (fr) | 2022-08-16 | 2024-02-22 | Iome Bio | Nouveaux anticorps anti-rgmb |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ATE219517T1 (de) * | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
DK0985039T3 (da) | 1997-06-12 | 2008-06-09 | Novartis Int Pharm Ltd | Kunstige antistof-polypeptider |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
EP1651659A4 (fr) | 2003-08-07 | 2008-09-17 | Epitomics Inc | Methodes destinees a humaniser des anticorps monoclonaux de lapin |
MY163032A (en) * | 2005-12-29 | 2017-07-31 | Centocor Inc | Human anti-il-23 antibodies, compositions, methods and uses |
WO2008004834A1 (fr) | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Anticorps monoclonal humanisé à forte liaison au récepteur de facteur de croissance épidermique, récepteur egf |
MX343879B (es) | 2007-05-21 | 2016-11-25 | Alderbio Holdings Llc | Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados. |
EP2752428B8 (fr) | 2008-06-25 | 2020-02-26 | Novartis Ag | Humanisation d'anticorps de lapins au moyen d'une région charpente d'anticorps universelle |
US8193235B2 (en) | 2009-06-12 | 2012-06-05 | University Of Kansas | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state |
US10078085B2 (en) * | 2012-08-22 | 2018-09-18 | Mogam Biothechnology Institute | Screening and engineering method of super-stable immunoglobulin variable domains and their uses |
IL243311B (en) * | 2013-06-26 | 2022-07-01 | Numab Therapeutics AG | New frameworks for antibodies |
CN105940014A (zh) * | 2013-10-25 | 2016-09-14 | 努马布有限公司 | 双特异性构造及其在治疗各种疾病中的用途 |
AU2016278586B2 (en) | 2015-06-15 | 2022-05-19 | Numab Therapeutics AG | Hetero-dimeric multi-specific antibody format |
-
2017
- 2017-09-20 EP EP17192206.5A patent/EP3459968A1/fr not_active Withdrawn
-
2018
- 2018-09-19 EP EP18773174.0A patent/EP3684802A1/fr active Pending
- 2018-09-19 US US16/648,588 patent/US11421035B2/en active Active
- 2018-09-19 CA CA3073882A patent/CA3073882A1/fr active Pending
- 2018-09-19 AU AU2018335823A patent/AU2018335823A1/en active Pending
- 2018-09-19 WO PCT/EP2018/075377 patent/WO2019057787A1/fr unknown
- 2018-09-19 CN CN201880060278.4A patent/CN111133000A/zh active Pending
- 2018-09-19 JP JP2020515647A patent/JP2020535799A/ja active Pending
- 2018-09-19 MA MA050159A patent/MA50159A/fr unknown
-
2022
- 2022-08-22 US US17/821,199 patent/US20230242651A1/en active Pending
-
2023
- 2023-05-31 JP JP2023090016A patent/JP2023115024A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3459968A1 (fr) | 2019-03-27 |
JP2023115024A (ja) | 2023-08-18 |
US11421035B2 (en) | 2022-08-23 |
CN111133000A (zh) | 2020-05-08 |
US20230242651A1 (en) | 2023-08-03 |
US20200255533A1 (en) | 2020-08-13 |
JP2020535799A (ja) | 2020-12-10 |
AU2018335823A1 (en) | 2020-02-27 |
CA3073882A1 (fr) | 2019-03-28 |
EP3684802A1 (fr) | 2020-07-29 |
WO2019057787A1 (fr) | 2019-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50159A (fr) | Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps | |
MA49043A (fr) | Formulation stable d'anticorps | |
MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
MA42924A (fr) | Variants optimisés d'anticorps anti-vegf | |
MA47494A (fr) | Nouvelles utilisations d'anticorps anti-sirpg | |
MA50505A (fr) | Anticorps 2 + 1 bispécifiques (contorsbodies) | |
MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
MA56006A (fr) | Formulations sous-cutanées d'anticorps her2 | |
MA51232A (fr) | Indane-amines utiles en tant qu'antagonistes de pd-l1 | |
MA53905A (fr) | Anticorps stabilisant trem2 | |
MA46180A (fr) | Analogues de l'amyline | |
EA201791590A1 (ru) | Антитела к tau и их применение | |
MA51903A (fr) | Formulations d'anticorps b7-h4 | |
MA47736A (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
MA54052A (fr) | Formulation d'anticorps | |
FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
FR3056393B1 (fr) | Orthese d'extension de machoires | |
DK3720433T3 (da) | Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom | |
MA53218A (fr) | Antagonistes de l'intégrine | |
MA54139A (fr) | Formulation d'anticorps | |
MA45552A (fr) | Compositions destinées au traitement de l'amylose | |
MA56049A (fr) | Formulations stabilisées contenant des anticorps anti-angptl3 | |
MA53831A (fr) | Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques | |
MA45602A (fr) | Anticorps anti-apoc3 et leurs méthodes d'utilisation | |
MA53466A (fr) | Formulation stable d'anticorps anti-osmr |